News - Genentech

Filter

Current filters:

Genentech

Popular Filters

10 to 34 of 60 results

FDA advisory panel backs new indication for Genentech's Perjeta

13-09-2013

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

Mylan enters Tarceva settlement agreement

24-07-2013

US generics firm Mylan (Nasdaq: MYL) has entered into a settlement agreement with OSI Pharmaceuticals,…

GenentechGenericsLegalMylan LaboratoriesNorth AmericaOncologyOSI PharmaceuticalsPatentsPfizerTarceva

US Court denies re-hearing of Arzerra patent case

16-07-2013

Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

Conditional EU approval for Roche basal cell carcinoma drug

15-07-2013

The European Commission has granted conditional approval to Swiss drug major Roche's (ROG: SIX) Erivedge…

BiotechnologyCurisErivedgeEuropeGenentechOncologyPharmaceuticalRegulationRoche

Immunocore and Genentech collaborate to develop ImmTACs for multiple cancer targets

01-07-2013

Immunocore, an Oxford, UK-based biotechnology company developing novel biological drugs known as ImmTACs…

BiotechnologyGenentechLicensingOncologyResearchRoche

PDL files for arbitration for alleged royalties underpayments by Genentech

11-06-2013

USA-based PDL BioPharma (Nasdaq: PDLI) revealed today (June 11) that it has filed a Notice of Arbitration…

BiotechnologyFinancialGenentechLegalPDL BioPharmaPharmaceuticalRoche

Roche's Avastin extends lives of cervical cancer patients; positive in glioblastoma

03-06-2013

Data presented from the study, known as GOG240, showed that the addition of Swiss pharma major Roche's…

AvastinBiotechnologyGenentechOncologyPharmaceuticalResearchRoche

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Strong initial data on Genentech's obinutuzumab in most common blood cancer

16-05-2013

Genentech, the biotech subsidiary of Swiss drug major Roche Group (ROG: SIX), has announced positive…

BiotechnologyGA101GenentechobinutuzumabOncologyResearchRoche

Pharmaco-invasive strategy including Metalyse comparable to primary PCI for STEMI patients

11-03-2013

New data presented at the American College of Cardiology 62nd Annual Scientific Sessions and Expo demonstrate…

Boehringer IngelheimCardio-vascularGenentechMetalysePharmaceuticalResearchTNKase

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

US FDA approves Roche's late-stage breast cancer drug Kadcyla

25-02-2013

The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Italy's antitrust body investigating Roche and Novartis for alleged cartel

21-02-2013

The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…

AvastinBiotechnologyEuropeGenentechLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Genentech enters $111 million drug discovery pact with RQx Pharma

13-02-2013

California, USA-based privately-held RQx Pharmaceuticals said yesterday that it has entered into a drug…

BiotechnologyGenentechLicensingRocheRQx Pharmaceuticals

US biotech giants lobbying to block biosimilars, NTY claims

31-01-2013

Some of the USA's biggest biotechnology companies are lobbying intensively to limit generic competition…

AmgenBiotechnologyGenentechGenericsNorth AmericaPoliticsRegulation

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

San Antonio breast cancer meeting highlights

10-12-2012

There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…

AvastinBiotechnologyEisaiGenentechHerceptinOncologyPerjetaPharmaceuticalResearchRoche

Curis in-licenses cancer candidate from Genentech

30-11-2012

US drug development firm Curis (Nasdaq: CRIS) that it has licensed from Genentech, a subsidiary of Swiss…

BiotechnologyCurisGDC-0917GenentechGUDC-427LicensingOncologyPharmaceuticalRoche

FDA Approves Abraxane for NSCLC and expands indication for Actemra

15-10-2012

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

Genentech's T-DM1 significantly improved survival for metastatic breast cancer patients

29-08-2012

Swiss drug major Roche (ROG: SIX) US subsidiary Genentech has announced updated results from the Phase…

BiotechnologyGenentechOncologyPharmaceuticalRegulationResearchRocheT-DM1trastuzumab emtansine

Roche gains FDA approval for Lucentis in diabetic macular edema

13-08-2012

US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX) announced on Friday that…

GenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

10 to 34 of 60 results

Company Spotlight

Fibrotech

Fibrotech

Back to top